Literature DB >> 9420029

Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120.

K De Vreese1, I Van Nerum, K Vermeire, J Anné, E De Clercq.   

Abstract

The bicyclams are a new class of anti-human immunodeficiency virus (anti-HIV) compounds targeted at viral entry. From marker rescue experiments, it appears that the envelope gp120 glycoprotein plays an important role in the anti-HIV activity of the bicyclams. Bicyclam-resistant strains contain a number of amino acid changes scattered over the V2 to V5 region of gp120. Experiments aimed at estimating the relative importance of particular amino acid changes with regard to the overall resistance pattern are described. The sequences of some partially bicyclam-resistant virus strains, obtained during the resistance development process, were analyzed, and the corresponding 50% effective concentrations were determined. Selected mutations observed in bicyclam-resistant strains were introduced in the wild-type background by site-directed mutagenesis. In addition, some amino acids were back-mutated to their wild-type counterparts in an otherwise JM3100-resistant strain. The sensitivities of these mutant viruses to bicyclams were determined. Construction of chimeric viruses, carrying the V3 loop of JM3100-resistant virus in a wild-type HIV type 1 HXB2 background, enabled us to investigate the importance of the mutations in the V3 loop of JM3100-resistant virus. From the results described in the report, it can be concluded that single amino acid substitutions do not influence the observed resistance to JM3100. Also, the mutations in the V3 loop are not sufficient to engender even a partially resistant phenotype. We postulate that the overall conformation of gp120 determines the degree of sensitivity or resistance of HIV strains to bicyclams.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9420029      PMCID: PMC164179     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding.

Authors:  K De Vreese; D Reymen; P Griffin; A Steinkasserer; G Werner; G J Bridger; J Esté; W James; G W Henson; J Desmyter; J Anné; I De Clercq
Journal:  Antiviral Res       Date:  1996-03       Impact factor: 5.970

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

Authors:  D Schols; J A Esté; G Henson; E De Clercq
Journal:  Antiviral Res       Date:  1997-08       Impact factor: 5.970

4.  The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.

Authors:  K de Vreese; V Kofler-Mongold; C Leutgeb; V Weber; K Vermeire; S Schacht; J Anné; E de Clercq; R Datema; G Werner
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1.

Authors:  J P Moore; R L Willey; G K Lewis; J Robinson; J Sodroski
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

6.  Single basic amino acid substitutions at position 302 or 320 in the V3 domain of HIV type 1 are not sufficient to alter the antiviral activity of dextran sulfate and heparin.

Authors:  T Okada; M E Gurney
Journal:  AIDS Res Hum Retroviruses       Date:  1995-05       Impact factor: 2.205

7.  Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.

Authors:  G J Bridger; R T Skerlj; D Thornton; S Padmanabhan; S A Martellucci; G W Henson; M J Abrams; N Yamamoto; K De Vreese; R Pauwels
Journal:  J Med Chem       Date:  1995-01-20       Impact factor: 7.446

8.  Local and global structural properties of the HIV-MN V3 loop.

Authors:  P Catasti; J D Fontenot; E M Bradbury; G Gupta
Journal:  J Biol Chem       Date:  1995-02-03       Impact factor: 5.157

9.  Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.

Authors:  E De Clercq; N Yamamoto; R Pauwels; J Balzarini; M Witvrouw; K De Vreese; Z Debyser; B Rosenwirth; P Peichl; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.

Authors:  J A Esté; K De Vreese; M Witvrouw; J C Schmit; A M Vandamme; J Anné; J Desmyter; G W Henson; G Bridger; E De Clercq
Journal:  Antiviral Res       Date:  1996-03       Impact factor: 5.970

View more
  3 in total

1.  ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.

Authors:  Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

2.  Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.

Authors:  Jessamina E Harrison; Jonathan B Lynch; Luz-Jeannette Sierra; Leslie A Blackburn; Neelanjana Ray; Ronald G Collman; Robert W Doms
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

3.  R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch.

Authors:  Silvana Tasca; Siu-Hong Ho; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.